CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).
lung cancer
-
February 07, 2019Read more »
-
March 12, 2018Read more »
My mother was diagnosed with lung cancer and had been treated with a standard chemotherapy combination therapy and Xalkori (crizotinib), the other first in class before Alecensa...
-
February 13, 2018Read more »
In 2015, an estimated 221,200 people in the U.S. will be diagnosed with lung cancer, which is 13 percent of all cancer diagnoses.
-
February 09, 2016Read more »
A new treatment that targets a specific type of lung cancer has received FDA approval.
